CD276 and nonpapillary renal cell carcinoma: Recently, therelationship between CD276 and ccRCC has gradually become a research hotspot.Numerous clinical studies have confirmed that tumor tissues in ccRCC patientsgenerally show increased CD276 expression, and the higher the level of CD276, thegreater the risk of recurrence or metastasis, indicating that CD276 is an importantbiomarker for predicting the clinical prognosis of ccRCC patients [14–16].